| Autor: |
Miyake, Makito, Shimizu, Takuto, Nishimura, Nobutaka, Kiba, Keisuke, Maesaka, Fumisato, Oda, Yuki, Tachibana, Akira, Tomizawa, Mitsuru, Ohmori, Chihiro, Matsumura, Yoshiaki, Ichikawa, Kazuki, Mizobuchi, Shinichiro, Yoshikawa, Takanosuke, Hori, Shunta, Morizawa, Yosuke, Gotoh, Daisuke, Nakai, Yasushi, Anai, Satoshi, Torimoto, Kazumasa, Aoki, Katsuya, Tanaka, Nobumichi, Fujimoto, Kiyohide |
| Zdroj: |
Clinical Genitourinary Cancer; 20210101, Issue: Preprints |
| Abstrakt: |
The optimal first-line chemotherapy regimen and dose adjustment for cisplatin-unfit patients with advanced, unresectable and/or metastatic urothelial carcinoma remains unclear.We investigated the association between response to first-line chemotherapy and response to subsequent pembrolizumab treatment.The response to pembrolizumab after dose-reduced cisplatin plus gemcitabine chemotherapy was inferior to that after carboplatin plus gemcitabine chemotherapy.The dose-reduced cisplatin plus gemcitabine chemotherapy is not recommended for cis-unfit patients with advanced urothelial carcinoma in the era of immune checkpoint inhibitors. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect